India Globalization Capital, Inc.: insider trades · United States · SEC (Form 4)

About India Globalization Capital, Inc.

India Globalization Capital, Inc., now operating as IGC Pharma, Inc., is a U.S.-based clinical-stage biotechnology company listed on NYSE American (part of the broader U.S. listed-equity universe often grouped by investors with NYSE/NASDAQ names). The company is headquartered in Potomac, Maryland, and was incorporated in Maryland in 2005. Over time, it has evolved from a blank-check style vehicle into a neuroscience- and AI-focused small-cap biotech platform. For investors, the key takeaway is that IGC is not a diversified industrial or consumer business; it is a development-stage healthcare company whose equity story is driven primarily by clinical milestones, regulatory execution, and capital needs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518526000030/igc424b5010526.htm?utm_source=openai)) IGC Pharma’s core business is the development of therapies for neurological and neurodegenerative disorders, with Alzheimer’s disease at the center of its strategy. Its lead asset, IGC-AD1, is designed to address agitation associated with Alzheimer’s disease and is being advanced through Phase 2B clinical development according to SEC filings and company communications. The company also references pipeline and research efforts in epilepsy, Tourette syndrome, sleep disorders, chronic pain, PMS, dysmenorrhea, and other wellness-related or neuropsychiatric applications. In addition to its drug-development work, IGC is building AI-enabled capabilities intended to improve drug discovery, clinical-trial design, and patient-targeting models. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518526000030/igc424b5010526.htm?utm_source=openai)) Geographically, IGC has a relatively small but strategically distributed footprint. Its principal executive offices are in Potomac, Maryland. The company’s website also describes clinical research activity in Colombia, accounting and analytics functions in India, and a manufacturing/processing facility in Vancouver, Washington. That footprint suggests a hybrid operating model: U.S.-listed, U.S.-headquartered, with select international support functions and a limited manufacturing base. Commercially, however, the company remains concentrated on the U.S. capital markets and the U.S.-led biotech ecosystem rather than on a broad global sales network. ([igcpharma.com](https://igcpharma.com/about/?utm_source=openai)) Recent developments indicate a strategic tightening around the company’s pharmaceutical core. In 2025, IGC reported a transition away from white-label manufacturing revenues toward its pharmaceutical and AI assets, while also noting continued progress in patient enrollment for its ongoing trial. Later SEC disclosures described the sale of assets tied to its Vancouver, Washington facility, signaling further portfolio rationalization. Additional filings show corporate actions such as an increase in authorized shares and a change in fiscal year-end, both of which are often relevant to small-cap biotech investors because they can affect financing flexibility and reporting cadence. Overall, IGC remains a high-risk, high-optionalty biotech story: the upside case depends on clinical success and platform validation, while the downside remains tied to dilution, execution risk, and the uncertain economics of early-stage drug development. ([igcpharma.com](https://igcpharma.com/igc-pharma-reports-financial-results-and-clinical-progress-for-the-period-ended-december-31-2025/?utm_source=openai))